Leu208Val and ILe181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population [3]

Blood

Volumn 100, Issue 2, 2002, Pages 734-

  Zarza, José ^a   Hermida, José ^a   Montes, Ramón ^a   Alberca, Ignacio ^a   López, María Luz ^a   Rocha, Eduardo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; MUTANT PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; GENOTYPE; HUMAN; INTERNATIONAL STANDARD UNIT; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SPAIN;

EID: 0037100519     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0821     Document Type: Letter

References (8)

1. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics
2. Risk factors for complications of chronic anticoagulation: A multicenter study
3. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
4. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
5. Genetic modulation of oral anticoagulation with warfarin
6. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on acenocoumarol sensitivity
7. Pharmacogenetics of warfarin elimination and its clinical implications
8. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients